| Literature DB >> 21129610 |
N Silvestris1, E Maiello, F De Vita, S Cinieri, D Santini, A Russo, S Tommasi, A Azzariti, G Numico, S Pisconti, D Petriella, V Lorusso, A Millaku, G Colucci.
Abstract
Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21129610 DOI： 10.1016/S0305-7372(10)70020-7
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111